| Molecular basis of receptor binding and antibody neutralization of Omicron Q Hong, W Han, J Li, S Xu, Y Wang, C Xu, Z Li, Y Wang, C Zhang, ... Nature 604 (7906), 546-552, 2022 | 155 | 2022 |
| Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies Y Wang, C Liu, C Zhang, Y Wang, Q Hong, S Xu, Z Li, Y Yang, Z Huang, ... Nature communications 13 (1), 871, 2022 | 131 | 2022 |
| Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections C Zhang, Y Wang, Y Zhu, C Liu, C Gu, S Xu, Y Wang, Y Zhou, Y Wang, ... Nature communications 12 (1), 264, 2021 | 96 | 2021 |
| Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement J Zang, C Gu, B Zhou, C Zhang, Y Yang, S Xu, L Bai, R Zhang, Q Deng, ... Cell Discovery 6 (1), 61, 2020 | 59 | 2020 |
| Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM Y Wang, C Xu, Y Wang, Q Hong, C Zhang, Z Li, S Xu, Q Zuo, C Liu, ... Nature communications 12 (1), 7345, 2021 | 52 | 2021 |
| Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection J Zang, Y Zhu, Y Zhou, C Gu, Y Yi, S Wang, S Xu, G Hu, S Du, Y Yin, ... Cell Discovery 7 (1), 71, 2021 | 32 | 2021 |
| Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein S Xu, Y Wang, Y Wang, C Zhang, Q Hong, C Gu, R Xu, T Wang, Y Yang, ... Emerging Microbes & Infections 11 (1), 351-367, 2022 | 23 | 2022 |
| Neutralizing potency of prototype and omicron RBD mRNA vaccines against omicron variant J Zang, Y Yin, S Xu, W Qiao, Q Liu, D Lavillette, C Zhang, H Wang, ... Frontiers in immunology 13, 908478, 2022 | 18* | 2022 |
| Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody T Li, H Cai, Y Zhao, Y Li, Y Lai, H Yao, LD Liu, Z Sun, MF van Vlissingen, ... EMBO Molecular Medicine 13 (12), e14544, 2021 | 18 | 2021 |
| Elicitation of broadly neutralizing antibodies against B. 1.1. 7, B. 1.351, and B. 1.617. 1 SARS-CoV-2 variants by three prototype strain-derived recombinant protein vaccines Y Yang, J Zang, S Xu, X Zhang, S Yuan, H Wang, D Lavillette, C Zhang, ... Viruses 13 (8), 1421, 2021 | 7 | 2021 |
| An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines F Liu, C Feng, S Xu, Q Wu, J Tang, Y Chen, R Xu, F Chen, N Gao, Z Xu, ... Vaccine 40 (9), 1208-1212, 2022 | 4 | 2022 |
Chao Zhang (张超)Fudan University在 fudan.edu.cn 的电子邮件经过验证
